Brazil Nuclear Imaging Market Size

Brazil Nuclear Imaging Market Analysis

The Brazil Nuclear Imaging Market size is estimated at USD 179.87 million in 2024, and is expected to reach USD 212.5 million by 2029, growing at a CAGR of 3.39% during the forecast period (2024-2029).

The pandemic had an adverse effect on the country. Cancer patients were particularly affected by these activities since the length of time needed for screens, diagnoses, and treatment beginning had a negative impact on outcomes. Brazil's Ministry of Health (MoH) established an Emergency Operations Centre (COE) in January 2020 to respond to potentially affected cases, educate medical personnel nationwide, and offer tests and clinical practice recommendations. The Oswald Cruz Foundation (Fiocruz), the Pan American Health Organization (PAHO), and Anvisa (the Brazilian Health Regulatory Agency-Agencia Nacional de Vigilancia Sanitaria) made up the COE (PAHO). The COVID-19 scenario has also given market participants numerous possibilities to fortify their positions and acquire a competitive edge through strategic partnerships, mergers, or acquisitions. For instance, in June 2021, Isotope JSC, a division of Rusatom Healthcare JSC, Rosatom's radiation technologies integrator, agreed to a five-year supply agreement for lutetium-177 and actinium-225, the two most promising medical isotopes in radiopharma, with Brazil's Nuclear and Energy Research Institute. The agreement enhances ROSATOM's position as the main provider of radioisotopes to the markets in Latin America. Thus, the market was adversely affected by the pandemic.

Brazil is expected to contribute to the market's expansion due to the increased prevalence of diseases, technical advancements, the introduction of novel radiopharmaceuticals for diagnosis, and the development of molecular imaging. Additionally, almost 10% of all hospital admissions in Brazil are related to cardiovascular disorders, according to a report published in June 2020 with the title "Characterization of Brazilian hospital admissions owing to cardiovascular diseases: a longitudinal study." It also came to the conclusion that a significant portion of hospital admissions related to cardiovascular diseases are caused by stroke (11.4%), heart failure (21.3%), and other ischemic heart disorders (13.3%). The SPECT technique, which employs thallium-201 (201Tl), is preferable for the evaluation of cardiac perfusion and the integrity of the cellular membrane, according to the "Update of the Brazilian Guideline on Nuclear Cardiology - 2020" published in SciELO Brasil in February 2020. Such recommendations and guidelines are anticipated to accelerate market expansion. Eckert & Ziegler began shipping Technetium-99 generators to Brazil in August 2021. The Brazilian health agency ANVISA recently granted a license to the subsidiary Eckert & Ziegler Brasil Comercial Ltda., making it the first and only private company authorized to import and sell technetium generators. The first clients include two renowned hospitals in the greater Sao Paulo region. . Around 500 hospitals and clinics in the nation receive their medical supplies and radioisotopes from Eckert & Ziegler. Thus, the abovementioned factors are expected to increase market growth.

However, the lack of proper reimbursement and stringent regulatory approval procedures, and the high cost of equipment, are expected to hinder the market growth in Brazil.